Corbus Pharmaceuticals to Present at the Guggenheim SMID Cap Biotech Conference. 01/08/2025 • 8:00 AM EST. Corbus Pharmaceuticals Announces that Clinical Data for CRB-701 from Western Dose Escalation Study to be Presented at ASCO GU 2025. Investor Information View Investor Relations. CRBP. Nasdaq. Volume.

Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, develops products to defeat serious illness.

Corbus Logo.jpg. Format JPEG. Source Corbus Pharmaceuticals Holdings, Inc. Downloads. Original Large Medium Small About Us. GlobeNewswire is one of the world's largest newswire distribution ...

Find the Corbus Pharma style guide with brand assets such as logos, colors, fonts, and more.

18 hours ago · Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific ...

18 hours ago · Corbus Pharmaceuticals announced that the abstract for its first-in-human dose escalation clinical study conducted in the United States and Europe of CRB-701 has been released.The corresponding up ...

1 day ago · The word on The Street in general, suggests a Strong Buy analyst consensus rating for Corbus Pharmaceuticals with a $56.25 average price target, a 454.19% upside from current levels.

Corbus is a precision oncology company committed to helping people defeat serious illness by bringing innovative scientific approaches to well understood biological pathways.

Corbus’ pipeline encompasses two different approaches to oncology with different risk profiles: a next-generation Nectin -4 Antibody Drug Conjugate (ADC) and monoclonal antibodies that target integrins to inhibit activation of TGFβ. Corbus is headquartered in Norwood, Massachusetts.

Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage company focused on the development and commercialization of novel medicines designed to target the endocannabinoid system.